Literature DB >> 9062950

Hepatitis C virus infection and autoimmunity.

R W McMurray1, K Elbourne.   

Abstract

Hepatitis C virus (HCV) infection has been associated with a plethora of immune and autoimmune perturbations. We review serological and clinical autoimmune manifestations associated with HCV infection, discuss treatment regimens for HCV-related autoimmune diseases, and present a framework for understanding HCV-associated autoimmune disease by performing a computerized literature search from which representative articles were used and referenced. The immune response to HCV may include the development of cryoglobulins, rheumatoid factor, antinuclear antibodies (ANA), anticardiolipin, antithyroid, anti-liver/kidney/microsomal antibodies (anti-LKM), as well as HCV/anti-HCV immune complex formation and deposition. HCV infection is a significant cause of mixed essential cryoglobulinemia, which may then be complicated by cryoglobulinemic glomerulonephritis, vasculitis, or neuropathy. It has also been associated with membranous and membranoproliferative glomerulonephritis. Subsets of autoimmune hepatitis patients are infected with HCV and evidence suggests that HCV is a causative agent of antithyroid antibodies and autoimmune thyroid disease. Although cause-and-effect remain to be proved, there are reports of HCV infection preceding or coincident with polyarthritis, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and polymyositis/dermatomyositis (PM/DM). HCV-infected patients also have a high incidence of sialoadenitis, and reports of low-grade lymphoproliferative malignancies have emerged. However, HCV is not a major causative factor for most autoimmune diseases. Optimal treatment for HCV-related autoimmune disease remains to be determined. Interferon alpha (IFN alpha) has successfully reduced viremia/transaminitis, cryoglobulins, proteinuria, and nephritis, but recurrent disease manifestations are frequent after discontinuation of therapy. Moreover, IFN alpha may precipitate or exacerbate autoimmune disease symptoms. HCV-related autoimmune disease also has been treated successfully with corticosteroids, azathioprine, and cyclophosphamide, although HCV viremia persists and may worsen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062950     DOI: 10.1016/s0049-0172(97)80005-4

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  35 in total

1.  The diversity of autoantibodies to P-ribosomal: the infectious-autoimmunity plot.

Authors:  Yehuda Shoenfeld
Journal:  J Mol Med (Berl)       Date:  2007-09       Impact factor: 4.599

Review 2.  Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia.

Authors:  Merav Lidar; Noga Lipschitz; Nancy Agmon-Levin; Pnina Langevitz; Ori Barzilai; Maya Ram; Bat-Sheba Porat-Katz; Nicola Bizzaro; Jan Damoiseaux; Jan Willem Cohen Tervaert; Salvatore deVita; Stefano Bombardieri; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

3.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

4.  Persistence of a large population of exhausted monoclonal B cells in mixed cryoglobuliemia after the eradication of hepatitis C virus infection.

Authors:  Marcella Visentini; Valentina Conti; Maria Cagliuso; Giulia Siciliano; Carolina Scagnolari; Milvia Casato; Massimo Fiorilli
Journal:  J Clin Immunol       Date:  2012-03-02       Impact factor: 8.317

5.  Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemia.

Authors:  S Migliaresi; A Bresciani; L Ambrosone; M Spera; D Barbarulo; V Lombari; G Pirozzi; G Borgia; M L Lombardi; G Tirri; C Manzo
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

Review 6.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

7.  Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane).

Authors:  Dina C Nacionales; Kindra M Kelly; Pui Y Lee; Haoyang Zhuang; Yi Li; Jason S Weinstein; Eric Sobel; Yoshiki Kuroda; Jun Akaogi; Minoru Satoh; Westley H Reeves
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

8.  Is there an association between pemphigus and hepatitis viruses? A population-based large-scale study.

Authors:  Khalaf Kridin; Shira Zelber-Sagi; Doron Comaneshter; Arnon D Cohen
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

9.  Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome.

Authors:  K Mizuno; A Yachie; S Nagaoki; H Wada; K Okada; M Kawachi; T Toma; A Konno; K Ohta; Y Kasahara; S Koizumi
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

10.  Biological autoimmunity screening in hepatitis C patients by anti-HepG2 lysate and anti-heat shock protein 70.1 autoantibodies.

Authors:  B F F Chumpitazi; L Bouillet; M-T Drouet; L Kuhn; J Garin; J-P Zarski; C Drouet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.